Loading...
•
Sep 30, 2024
Equillium Q3 2024 Earnings Report
Equillium reported financial results for the third quarter of 2024 and provided corporate and clinical updates.
Key Takeaways
Equillium reported revenue of $12.2 million for the third quarter of 2024, compared to $8.9 million for the same period in 2023. Net loss for the quarter was approximately $7,000, or $(0.00) per basic and diluted share, compared to a net loss of $3.7 million, or $(0.11) per basic and diluted share, for the same period in 2023.
Retained rights to itolizumab following Ono partnership.
Positive interim analysis of Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease subjects.
Phase 2 ulcerative colitis study completed by partner Biocon.
Topline data from Phase 2 study in ulcerative colitis and Phase 3 EQUATOR study in aGVHD expected in Q1 2025.
Forward Guidance
Equillium believes that its cash, cash equivalents and short-term investments are sufficient to fund operations into the fourth quarter of 2025, assuming certain operational changes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...